黄灵曦, 谢建平. 结核分枝杆菌生物素合成途径是抗结核菌药物开发的新靶点J. 药学学报, 2024, 59(3): 503-510. DOI: 10.16438/j.0513-4870.2023-1040
引用本文: 黄灵曦, 谢建平. 结核分枝杆菌生物素合成途径是抗结核菌药物开发的新靶点J. 药学学报, 2024, 59(3): 503-510. DOI: 10.16438/j.0513-4870.2023-1040
HUANG Ling-xi, XIE Jian-ping. The biotin synthesis pathway in Mycobacteria tuberculosis is a new target for the development of anti-tuberculosis drugsJ. Acta Pharmaceutica Sinica, 2024, 59(3): 503-510. DOI: 10.16438/j.0513-4870.2023-1040
Citation: HUANG Ling-xi, XIE Jian-ping. The biotin synthesis pathway in Mycobacteria tuberculosis is a new target for the development of anti-tuberculosis drugsJ. Acta Pharmaceutica Sinica, 2024, 59(3): 503-510. DOI: 10.16438/j.0513-4870.2023-1040

结核分枝杆菌生物素合成途径是抗结核菌药物开发的新靶点

The biotin synthesis pathway in Mycobacteria tuberculosis is a new target for the development of anti-tuberculosis drugs

  • 摘要: 结核分枝杆菌(Mycobacterium tuberculosis) 感染导致的结核病仍然是全球主要的公共卫生难题。生物素即维生素H是脂肪酸生物合成、糖异生及氨基酸代谢等途径所需的辅因子。结核分枝杆菌无法从外界吸收生物素, 生物素的合成是分枝杆菌生物素的唯一来源。不同于经典的BioC-BioH、BioI-BioW途径及非经典的BioZ途径, 结核分枝杆菌早期阶段通过“BioC-BioH(2)”途径合成生物素。本综述重点总结结核分枝杆菌独特的生物素合成途径及其关键基因, 尤其是该途径及生物素依赖性羧化酶对结核病一二线药物的响应, 以及靶向生物素合成的抑制剂和天然产物。

     

    Abstract: Mycobacterium tuberculosis, responsible for tuberculosis (TB), remains a major health problem worldwide and is one of the infectious diseases causing increased morbidity and mortality worldwide. Biotin, namely vitamin H, is an important cofactor necessary for fatty acid biosynthesis, gluconeogenesis and amino acid metabolism in organisms including Mycobacterium tuberculosis. Due to its inability to ingestion biotin from outside, Mycobacterium tuberculosis can only obtain biotin through biotin biosynthesis. Different from the classical BioC-BioH, BioI-BioW and non-classical BioZ pathways, Mycobacterium tuberculosis synthesized biotin by "BioC-BioH(2)" pathway in the early stage. This review focuses on the unique biotin synthesis pathway of Mycobacterium tuberculosis and its key genes, especially the response of this pathway and biotin-dependent carboxylase to tuberculosis first-and second-line drugs, as well as inhibitors and natural products targeting biotin synthesis.

     

/

返回文章
返回